title: Evaluation of the XIENCE V everolimus eluting coronary stent system in the Asian population of the SPIRIT V single arm study. 2-year clinical follow-up data.
abstract: BACKGROUND
  Asian patients have a uniquely high risk for heart disease compared to other ethnicities. Past drug eluting stent trials have examined mainly populations of European heritage. As a significant proportion of the real world population in the SPIRIT V single arm study is Asian, the study provides insight into how this population responds to stenting with the XIENCE V Everolimus Eluting Coronary Stent (EES).
  
  
  RESULTS
  2,700 patients were enrolled at 93 sites in Europe, Asia Pacific and Canada between November 2006 and November 2007. 698 (26%) patients were recruited from Asian sites in India, China, Hong Kong, Malaysia, Singapore and Thailand. De novo coronary artery lesions of all patients were to be treated with up to 4 planned EES. Up to 2 year follow-up, major adverse cardiac events, myocardial infarction and target lesion revascularization rates were lower in the Asian subgroup than in the non-Asian subgroup. These results were mainly driven by better clinical outcomes in the Indian population. All populations showed similar low stent thrombosis rates.
  
  
  CONCLUSIONS
  These findings demonstrate the safety and efficacy of the EES when used in a real-world Asian population, known to be at higher risk for heart disease.
authors.affiliation: Escorts Heart Institute and Research Centre, New Delhi, India upendra.kaul@fortishealthcare.com
authors.forename: Upendra
authors.initials: U
authors.lastname: Kaul
authors.forename: Tejas M
authors.initials: TM
authors.lastname: Patel
authors.forename: Robaayah
authors.initials: R
authors.lastname: Zambahari
authors.forename: Ajit S
authors.initials: AS
authors.lastname: Mullasari
authors.forename: Vinay K
authors.initials: VK
authors.lastname: Bahl
authors.forename: Marrianne
authors.initials: M
authors.lastname: Stuteville
authors.forename: Cécile
authors.initials: C
authors.lastname: Dorange
authors.forename: Susan
authors.initials: S
authors.lastname: Veldhof
authors.forename: Eberhard
authors.initials: E
authors.lastname: Grube
mesh_terms: D001210:Asia, Southeastern; D044466:Asian People; D002681:China; D003324:Coronary Artery Disease / Q000208:ethnology* / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007194:India; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D009204:Myocardial Revascularization / Q000706:statistics & numerical data; D012086:Reoperation; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013927:Thrombosis / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus